Finances
Osimertinib Plus Chemotherapy Enhances Survival
Survival Improvement in patients with EGFR-mutant non-small cell lung cancer (NSCLC) has become a focal point in recent oncology research. The FLAURA2 study reveals that the combination of osimertinib with platinum-pemetrexed-based chemotherapy significantly enhances overall survival rates. This article delves into the comparative survival benefits, FDA approval status, and the Read more…